Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
29 January 2021Website:
http://nlspharma.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 15 Nov 2024 22:00:59 GMTDividend
Analysts recommendations
Institutional Ownership
NLSP Latest News
NLS Pharmaceutics (NASDAQ: NLSP ) stock is on the rise Monday after the clinical-stage biopharmaceutical company announced a merger agreement with Kadimastem. This agreement will see Kadimastem acquired by a wholly-owned subsidiary of NLS Pharmaceutics.
NLS Pharmaceutics (NASDAQ: NLSP ) stock is down on Thursday but that's only after the clinical-stage biopharmaceutical company's shares underwent a massive rally on Tuesday. Shares of NLSP stock closed out Tuesday, the prior day of trading due to the Juneteenth holiday on Wednesday, up 82.1%.
NLS Pharmaceutics (NASDAQ: NLSP ) stock is taking a beating on Monday as the company's shares come down from a rally on Friday. The news that sent shares of NLSP stock higher on Friday concerned an exclusive option to license in-license Aexon Labs' Dual Orexin Receptor Agonists platform.
Shares of NLS Pharmaceutics Ltd. NLSP, +19.57% gained 12% premarket on Monday after the Swiss clinical-stage biopharma company said it would proceed with phase 3 clinical studies of Mazindol ER, a treatment for narcolepsy.
NLS to Webcast its Event on Thursday, July 6, 2023, at 11:00 am ET ZURICH, SWITERLAND / ACCESSWIRE / June 30, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will postpone its webcast previously scheduled for today due to important developments impacting the timing of the company update.
Presentation to take place on Tuesday, June 20, 2023, at 10:30AM ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20, 2023, at 10:30 AM ET.
Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / June 19, 2023 / NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, including: Feedback from the SLEEP 2023 APSS Conference Initiation of the Phase 3 program AMAZE for Mazindol ER Pipeline Goals for 2023/2024 Key Financials Funding Strategy Update Corporate Development Webcast Information The event will be held June 30, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website here or at the SummitCast event page here.
Members of Executive Leadership Team to Discuss initiation of Phase 3, Pipeline updates, Key Financials, Corporate Development, and the other topics NLS to Webcast its Event Friday, June 30 at 11:00am ET ZURICH, SWITZERLAND / ACCESSWIRE / June 15, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, including: Feedback from the SLEEP 2023 APSS Conference Initiation of the Phase 3 program AWARE for Mazindol ER Pipeline Goals for 2023/2024 Key Financials Funding Strategy Update Corporate Development Webcast Information The event will be held June 30, 2023, at 11:00 am ET and will include a video stream on the Investors section of the Company's website here.
What type of business is NLS Pharmaceutics AG?
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.
What sector is NLS Pharmaceutics AG in?
NLS Pharmaceutics AG is in the Healthcare sector
What industry is NLS Pharmaceutics AG in?
NLS Pharmaceutics AG is in the Biotechnology industry
What country is NLS Pharmaceutics AG from?
NLS Pharmaceutics AG is headquartered in Switzerland
When did NLS Pharmaceutics AG go public?
NLS Pharmaceutics AG initial public offering (IPO) was on 29 January 2021
What is NLS Pharmaceutics AG website?
https://nlspharma.com
Is NLS Pharmaceutics AG in the S&P 500?
No, NLS Pharmaceutics AG is not included in the S&P 500 index
Is NLS Pharmaceutics AG in the NASDAQ 100?
No, NLS Pharmaceutics AG is not included in the NASDAQ 100 index
Is NLS Pharmaceutics AG in the Dow Jones?
No, NLS Pharmaceutics AG is not included in the Dow Jones index
When was NLS Pharmaceutics AG the previous earnings report?
No data
When does NLS Pharmaceutics AG earnings report?
Next earnings report date is not announced yet